The following are NIH-funded research studies currently ongoing in the Division of Rheumatology at UTMB:
GENISOS (Genetics vs. Environment in Scleroderma Outcomes Study) is a multi-center study. The main principal investigator at UTMB is Dr. Emilio Gonzalez.
"The PRECISION Trial"
This trial will look at the cardiovascular safety of celecoxib (Celebrex) in comparison to ibuprofen and naproxen - Dr. Emilio Gonzalez.
"Effects of statins on pro-inflammatory and pro-thrombotic markers in APS."
The main purpose of this study is to investigate whether a drug named "statin" (fluvastatin) that is currently used and approved to reduce the cholesterol in blood, is beneficial in reducing the risk of cardiovascular disease in patients with antiphospholipid antibodies and/or lupus. – Dr. Silvia Pierangeli and Dr. Emilio Gonzalez.
The UTMB Center for Global Health Education (CGHE) is dedicated to the training of tomorrow's global health work force to improve health for the people of Texas and around the world. Check out their website for more information on the global health programs and education going on in our department.
The department of internal medicine is developing evidence based clinical protocols which will be available in EPIC (as order sets) for use when admitting patients with these diagnoses. Their AIM is to standardize care and decrease length of stay and readmission rates.Currently available protocols are:
- CAP - Community Acquired Pneumonia Orderset
- Congestive Heart Failure (CHF)
- Chronic Obstructive Pulmonary Disease (COPD)
- Diabetic Ketoacidosis Adult, ICU
- General Medicine Admission
- Immunodeficiency Flow Panel
- MICU/CCU Admission Order Set
- Oral Analgesic Medicaitons
- Parenteral Opioids
- Sepsis, Adult ICU
All protocols can be found in the EPIC order set section.
The department of Internal Medicine has a large role in the Meaningful Use Initiative. Our participation is key for the success of the initiative. Please visit the meaningful use website for important communication and updates from the Meaningful Use Initiative.